Merus Labs International (NASDAQ: MSLI) and The Medicines (NASDAQ:MDCO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitabiliy and earnings.
Institutional and Insider Ownership
19.7% of Merus Labs International shares are owned by institutional investors. 7.9% of The Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Merus Labs International and The Medicines’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Merus Labs International | N/A | N/A | N/A | ($0.08) | -16.25 |
| The Medicines | $141.74 million | 18.67 | -$306.00 million | ($1.90) | -19.59 |
Merus Labs International has higher revenue, but lower earnings than The Medicines. The Medicines is trading at a lower price-to-earnings ratio than Merus Labs International, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Merus Labs International has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, The Medicines has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Merus Labs International and The Medicines, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Merus Labs International | 0 | 6 | 0 | 0 | 2.00 |
| The Medicines | 0 | 2 | 8 | 0 | 2.80 |
Merus Labs International currently has a consensus price target of $1.35, indicating a potential upside of 3.85%. The Medicines has a consensus price target of $55.00, indicating a potential upside of 47.73%. Given The Medicines’ stronger consensus rating and higher probable upside, analysts clearly believe The Medicines is more favorable than Merus Labs International.
Profitability
This table compares Merus Labs International and The Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Merus Labs International | -5.18% | -2.51% | -1.32% |
| The Medicines | -91.25% | -19.09% | -7.60% |
Summary
Merus Labs International beats The Medicines on 6 of the 11 factors compared between the two stocks.
About Merus Labs International
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.
